Evaluation strategies for measuring pneumococcal conjugate vaccine impact in low-resource settings.

Autor:	von Mollendorf C; Infection And Immunity, Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Australia.; Department Of Paediatrics, The University of Melbourne, Melbourne, Australia., Lim R; Infection And Immunity, Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Australia., Choummanivong M; Faculty of Public Health, University Of Health Sciences, Ministry of Health, Vientiane, Lao PDR., Sychareun V; Faculty of Public Health, University Of Health Sciences, Ministry of Health, Vientiane, Lao PDR., Vilivong K; Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao PDR., Lai JYR; Infection And Immunity, Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Australia., Chan J; Infection And Immunity, Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Australia., Dunne EM; Infection And Immunity, Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Australia.; Department Of Paediatrics, The University of Melbourne, Melbourne, Australia., Phommachanh S; Institute of Research and Education Development (IRED), University of Health Sciences, Ministry of Health, Vientiane, Lao PDR., Moore KA; Infection And Immunity, Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Australia., Ortika BD; Infection And Immunity, Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Australia., Gray A; Department Of Paediatrics, The University of Melbourne, Melbourne, Australia., Weaver R; Department Of Paediatrics, The University of Melbourne, Melbourne, Australia., Mayxay M; Faculty of Public Health, University Of Health Sciences, Ministry of Health, Vientiane, Lao PDR.; Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao PDR.; Centre For Tropical Medicine And Global Health, University Of Oxford, Oxford UK., Phetsouvanh R; Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao PDR.; Centre For Tropical Medicine And Global Health, University Of Oxford, Oxford UK., Datta SS; Division of Combating Communicable Disease, World Health Organization, Vientiane Lao PDR., Fox K; Expanded Programme on Immunization, Regional Office for the Western Pacific, World Health Organization, Manila, Philippines., Newton PN; Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao PDR.; Centre For Tropical Medicine And Global Health, University Of Oxford, Oxford UK.; Faculty of Infectious & Tropical Diseases, London School Of Hygiene And Tropical Medicine, London, UK., Mulholland KE; Infection And Immunity, Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Australia.; Department Of Paediatrics, The University of Melbourne, Melbourne, Australia.; Faculty of Infectious & Tropical Diseases, London School Of Hygiene And Tropical Medicine, London, UK., Nguyen CD; Infection And Immunity, Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Australia.; Department Of Paediatrics, The University of Melbourne, Melbourne, Australia., Dance DAB; Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao PDR.; Centre For Tropical Medicine And Global Health, University Of Oxford, Oxford UK.; Faculty of Infectious & Tropical Diseases, London School Of Hygiene And Tropical Medicine, London, UK., Satzke C; Infection And Immunity, Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Australia.; Department Of Paediatrics, The University of Melbourne, Melbourne, Australia.; Department Of Microbiology And Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia., Russell FM; Infection And Immunity, Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Australia.; Department Of Paediatrics, The University of Melbourne, Melbourne, Australia.
Jazyk:	angličtina
Zdroj:	Expert review of vaccines [Expert Rev Vaccines] 2022 Aug; Vol. 21 (8), pp. 1137-1145. Date of Electronic Publication: 2021 Aug 19.
DOI:	10.1080/14760584.2021.1965474
Abstrakt:	Objectives: Pneumococcal conjugate vaccines (PCVs) are effective in reducing pneumococcal disease. We measured 13-valent PCV (PCV13) effect on different pneumococcal outcomes using diverse studies in Lao People's Democratic Republic. Methods: Studies included: pre-PCV13 population-based record review of hospitalized childhood pneumonia cases; acute respiratory infection (ARI) study post-PCV13 to demonstrate effectiveness (VE) against hypoxic pneumonia; invasive pneumococcal disease (IPD) surveillance in all ages (2004-2018); carriage studies in children hospitalized with ARI (2013-2019); community carriage surveys pre- and post-PCV13. Results: Annual pneumonia incidence rate in children pre-PCV13 was 1,530 (95% confidence interval [CI] 1,477-1,584) per 100,000. Adjusted VE against hypoxic pneumonia was 37% (95% CI 6-57%). For IPD, 85% (11/13) of cases were due to vaccine-types pre-PCV13, and 43% (3/7) post-PCV13 in children aged <5 years; for ≥5 years, 61% (27/44) and 42% (17/40), respectively. For ARI cases, adjusted VE for vaccine-type carriage was 39% (95% CI 4-60) in <5 year olds; slightly higher than community surveys (23% [95% CI 4-39%] in 12-23 month olds). Conclusions: Despite limited baseline data, we found evidence of PCV13 impact on disease and carriage. Our approach could be used in similar settings to augment existing WHO PCV evaluation guidelines.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu